Could Vertex's growth story continue? Vertex Pharmaceuticals (VRTX 0.20%) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of cystic fibrosis (CF) failed along the development path. But the company continued to impress with its CF products and their revenue growth as well as its advancement of other non-CF candidates in the pipeline. If you'd invested $10,000 in Vertex five years ago, you would have ...